Plain-English translation of NCT04282044 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing a new cancer treatment called CRX100, which is made from your own immune cells. Researchers want to learn whether this medication is safe and whether it helps people with advanced solid cancers—either on its own or combined with another drug called pembrolizumab. The study will start by testing the treatment alone, then move to testing it in combination with the other drug.
Many people with advanced cancers don't respond well to current standard treatments, or their cancers come back after treatment. This trial exists to see if this new cell-based medication could offer hope to people whose cancers have stopped responding to existing options.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll first undergo a procedure called leukapheresis, where doctors collect some of your white blood cells to create your personalized treatment. Then you'll receive infusions of the medication every nine weeks for up to four doses (unless your doctor recommends more). You'll have regular clinic visits to check your health, blood work, and imaging scans to see how the cancer is responding. The entire study could take several months.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States